Scobie Heather M, Johnson Amelia G, Suthar Amitabh B, Severson Rachel, Alden Nisha B, Balter Sharon, Bertolino Daniel, Blythe David, Brady Shane, Cadwell Betsy, Cheng Iris, Davidson Sherri, Delgadillo Janelle, Devinney Katelynn, Duchin Jeff, Duwell Monique, Fisher Rebecca, Fleischauer Aaron, Grant Ashley, Griffin Jennifer, Haddix Meredith, Hand Julie, Hanson Matt, Hawkins Eric, Herlihy Rachel K, Hicks Liam, Holtzman Corinne, Hoskins Mikhail, Hyun Judie, Kaur Ramandeep, Kay Meagan, Kidrowski Holly, Kim Curi, Komatsu Kenneth, Kugeler Kiersten, Lewis Melissa, Lyons B Casey, Lyons Shelby, Lynfield Ruth, McCaffrey Keegan, McMullen Chelsea, Milroy Lauren, Meyer Stephanie, Nolen Leisha, Patel Monita R, Pogosjans Sargis, Reese Heather E, Saupe Amy, Sell Jessica, Sokol Theresa, Sosin Daniel, Stanislawski Emma, Stevens Kelly, Vest Hailey, White Kelly, Wilson Erica, MacNeil Adam, Ritchey Matthew D, Silk Benjamin J
MMWR Morb Mortal Wkly Rep. 2021 Sep 17;70(37):1284-1290. doi: 10.15585/mmwr.mm7037e1.
COVID-19 vaccine breakthrough infection surveillance helps monitor trends in disease incidence and severe outcomes in fully vaccinated persons, including the impact of the highly transmissible B.1.617.2 (Delta) variant of SARS-CoV-2, the virus that causes COVID-19. Reported COVID-19 cases, hospitalizations, and deaths occurring among persons aged ≥18 years during April 4-July 17, 2021, were analyzed by vaccination status across 13 U.S. jurisdictions that routinely linked case surveillance and immunization registry data. Averaged weekly, age-standardized incidence rate ratios (IRRs) for cases among persons who were not fully vaccinated compared with those among fully vaccinated persons decreased from 11.1 (95% confidence interval [CI] = 7.8-15.8) to 4.6 (95% CI = 2.5-8.5) between two periods when prevalence of the Delta variant was lower (<50% of sequenced isolates; April 4-June 19) and higher (≥50%; June 20-July 17), and IRRs for hospitalizations and deaths decreased between the same two periods, from 13.3 (95% CI = 11.3-15.6) to 10.4 (95% CI = 8.1-13.3) and from 16.6 (95% CI = 13.5-20.4) to 11.3 (95% CI = 9.1-13.9). Findings were consistent with a potential decline in vaccine protection against confirmed SARS-CoV-2 infection and continued strong protection against COVID-19-associated hospitalization and death. Getting vaccinated protects against severe illness from COVID-19, including the Delta variant, and monitoring COVID-19 incidence by vaccination status might provide early signals of changes in vaccine-related protection that can be confirmed through well-controlled vaccine effectiveness (VE) studies.
新冠病毒病(COVID-19)疫苗突破性感染监测有助于监测完全接种疫苗人群的疾病发病率和严重后果趋势,包括导致COVID-19的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的高传播性B.1.617.2(德尔塔)变异株的影响。对2021年4月4日至7月17日期间≥18岁人群中报告的COVID-19病例、住院和死亡情况,按疫苗接种状况进行了分析,涉及美国13个常规关联病例监测和免疫登记数据的辖区。在德尔塔变异株流行率较低(<50%的测序分离株;4月4日至6月19日)和较高(≥50%;6月20日至7月17日)的两个时期之间,未完全接种疫苗者与完全接种疫苗者相比,每周平均年龄标准化发病率比(IRR)从11.1(95%置信区间[CI]=7.8-15.8)降至4.6(95%CI=2.5-8.5),住院和死亡的IRR在相同的两个时期之间也有所下降,从13.3(95%CI=11.3-15.6)降至10.4(95%CI=8.1-13.3),从16.6(95%CI=13.5-20.4)降至11.3(95%CI=9.1-13.9)。研究结果与疫苗对确诊SARS-CoV-2感染的保护作用可能下降、但对COVID-19相关住院和死亡仍有较强保护作用相一致。接种疫苗可预防包括德尔塔变异株在内的COVID-19重症,按疫苗接种状况监测COVID-19发病率可能会提供疫苗相关保护变化的早期信号,这些信号可通过严格控制的疫苗效力(VE)研究得到证实。